CClinicalTrials.gg
CompletedNCT04949789Updated Feb 22, 2022

Pilot Study to Evaluate Efficacy of Botanical Extracts as Protein Amplifier for Skeletal Muscle Strength & Growth.

An interventional study of Placebo without Exercise and Placebo with Exercise in Muscle Strength, sponsored by Vedic Lifesciences Pvt. Ltd.. Completed at 1 site in India. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-22.

Sponsored by Vedic Lifesciences Pvt. Ltd. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

Sponsor proposes ingredients that when added to daily whey supplementation, can lead to increased muscle strength, improves sleep quality and reduction in fatigue level.

Read the detailed description

The present study is a randomized, blinded, placebo-controlled, pilot study. Approximately 40 males aged between ≥ 20 and ≤ 35 years, will be screened. Each trial arm will have at least 5 completed after accounting for dropout/withdrawal rate of 20%. The treatment duration for all the study participants will be 28 to 56 days (Day 56 is only applicable for participants with less than 10% increase in weight leg pressed for 1 RM on Day 28. All participants in arm 1 of study will have their end of study visit on Day 28).Sponsor proposes ingredients that when added to daily whey supplementation, can lead to increased muscle strength, improves sleep quality and reduction in fatigue level.

02

Conditions studied

  • Muscle Strength
03

In context

Lead sponsor

Vedic Lifesciences Pvt. Ltd. is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Males aged 20 - 35 years with active lifestyle moderate physical activity level as per International Physical Activity Questionnaire.
  2. Recreationally active but not participating in resistance type training on regular basis.
  3. Body mass index (BMI) 22 - 29.9 kg/ m2
  4. Participants with an Insomnia Severity Index score ≥7 and ≤14
  5. Ready to refrain from caffeinated products and intense strength/ endurance exercise for 24 hrs. prior to the exercise lab visit.
  6. Fasting Glucose ≤ 110 mg/ dl
  7. Systolic Blood Pressure ≤ 129 mm Hg and Diastolic Blood Pressure ≤ 89 mm Hg
  8. TSH (thyroid stimulating hormone) ≥0.4 and ≤ 4.9 mIU/L

Exclusion criteria

Exclusion Criteria:

  1. Engaged in structured weight training during the previous 12 months prior to screening.
  2. Presence of chronic disease.
  3. Changes in body weight more than 4.5 kg (10 pounds) in the past three months.
  4. Participants with uncontrolled hypertension.
  5. Participants who are diagnosed with Type II Diabetes Mellitus.
  6. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic, or neurologic disorders.
  7. Allergy to whey or herbal ingredients.
  8. Participants who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put them at unacceptable risk for participation in the study or may interfere with evaluations in the study or noncompliance with treatment or visits.
  9. Participants who have been part of a clinical trial within 90 days prior to the screening.
  10. Participants who have used whey or other supplemental proteins anytime in last 3 months
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Other
    Placebo without Exercise

    2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.

    Other: Placebo without Exercise

  • Other
    Placebo with Exercise

    2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.

    Other: Placebo with Exercise

  • Other
    IP I

    2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.

    Other: IP I

  • Other
    IP II

    2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.

    Other: IP II

  • Other
    IP III

    2 Capsules to be taken 30 minutes before breakfast. * Whey Protein (standardized for NLT 90% AA): 48 gms of Whey protein isolate (WPI) will be taken by participants daily in two divided doses of 24 gms dissolved in 200 ml of water with their breakfast and dinner. * On testing and exercise days, WPI with IP will be taken 30 mins prior to the exercise without breakfast consumption.

    Other: IP III

Interventions

  • OtherPlacebo without Exercise

    2 Capsules to be taken 30 minutes before breakfast.

  • OtherPlacebo with Exercise

    2 Capsules to be taken 30 minutes before breakfast.

  • OtherIP I

    2 Capsules to be taken 30 minutes before breakfast.

  • OtherIP II

    2 Capsules to be taken 30 minutes before breakfast.

  • OtherIP III

    2 Capsules to be taken 30 minutes before breakfast.

06

What researchers measure

Primary outcomes

  1. 1-Repetition Maximum

    The final weight lifted successfully for atleast 1 repetition but could not complete 3 repetition will be recorded as 1- RM. Change in muscle strength as indicated by increase in 1Repetition Maximum leg press weight

    Time frame: Day 0 to Day 28 and /or day56

Secondary outcomes

  1. Body fat composition: Lean Muscle Mass by Dual-energy X-ray absorptiometry

    Increase in lean muscle mass by DXA

    Time frame: Day 0 to Day 28 and /or day56

  2. Quality of Sleep: Modified Insomnia Severity Index

    Improvement in sleep quality as assessed by the modified Insomnia Severity Index

    Time frame: Day 0 to Day 28 and /or day56

  3. Visual Analogue Scale for Fatigue

    Reduction in fatigue level as assessed by the 11-point Visual Analogue scale for Fatigue

    Time frame: Day 0 to Day 28 and /or day56

  4. Mid-thigh Girth

    Increase in mid-thigh muscle-girth (prior to exercise) at midpoint between inguinal fold and superior border of patella.

    Time frame: Day 0 to Day 28 and /or day56

  5. Digestive diary

    Participants will be asked to fill out a paper/online digestive diary to monitor any significant changes that might occur to the digestive system due to the consumption of WPI and the IP. there should be No significant effect on digestive system as per participant digestive diary.

    Time frame: Day 0 to Day 28 and /or day56

07

Study locations

1 site
  • Vedic Lifesciences
    Mumbai, Maharashtra 411046, India
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04949789
Lead sponsor
Vedic Lifesciences Pvt. Ltd.
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Jun 17, 2021
Primary completion
Nov 17, 2021
Completion
Nov 17, 2021
Last update
Feb 22, 2022

Study contacts

Dr, Anjali Jain, BHMS
principal investigator · Vedic lifesciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion